Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.17) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock traded up $0.11 during trading hours on Tuesday, hitting $13.48. The company had a trading volume of 57,709 shares, compared to its average volume of 2,235,119. The firm has a 50-day moving average of $13.31 and a 200 day moving average of $15.21. The firm has a market cap of $1.13 billion, a PE ratio of -25.98 and a beta of 0.87. Corvus Pharmaceuticals has a one year low of $4.05 and a one year high of $26.95.

Insider Activity at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, Director David Scott Moore bought 21,700 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $11.53 per share, with a total value of $250,201.00. Following the completion of the acquisition, the director owned 21,700 shares of the company’s stock, valued at $250,201. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 19.70% of the company’s stock.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its holdings in Corvus Pharmaceuticals by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock valued at $5,448,000 after acquiring an additional 771,454 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Corvus Pharmaceuticals by 541.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 30,420 shares of the company’s stock worth $122,000 after purchasing an additional 25,681 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Corvus Pharmaceuticals by 9,501.8% during the 2nd quarter. Rhumbline Advisers now owns 75,950 shares of the company’s stock worth $304,000 after purchasing an additional 75,159 shares in the last quarter. Hsbc Holdings PLC bought a new position in shares of Corvus Pharmaceuticals in the second quarter worth $332,000. Finally, New York State Common Retirement Fund bought a new position in shares of Corvus Pharmaceuticals in the second quarter worth $95,000. Institutional investors and hedge funds own 46.64% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CRVS. Wall Street Zen lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. Finally, The Goldman Sachs Group started coverage on Corvus Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $40.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.33.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.